Table 2

Characteristics of SARS-CoV-2 Delta and Omicron variant cases, Denmark, 22 November–7 December 2021

Number of Deltaa cases (n = 19,137) % of all Deltaa cases Number of Omicron cases (n = 785) % of all Omicron cases
0–9 3,081 16 30 3.8
10–14 2,434 13 23 2.9
15–19 962 5.0 102 13
20–29 2,317 12 214 27
30–39 2,548 13 110 14
40–49 2,973 16 111 14
50–64 2,952 15 144 18
≥ 65 1,870 10 51 6.5
Female 9,637 50 352 45
Male 9,500 50 433 55
Yesb NA 56 7.1
No NA 601 77
Unknown NA 128 16
Not vaccinated 8,199 44 111 14
Startedd 484 2.6 19 2.4
Vaccinatede 9,269 50 599 76
Booster vaccinationf 597 3.2 56 7.1
c,g
Yes 160 0.9 34 4.3
No 18,389 99 751 96
Yes NA 509 65
No NA 157 20
Unknown NA 119 15
Yes 290 1.5 9 1.2
Yes 22 0.11 1 0.13
Yes 14 0.07 0 0

NA: not applicable; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

a Based on WGS-confirmed cases with sampling date from 22 November–7 December 2021.

b South Africa (n = 16), Germany, Spain, Tanzania, Nigeria, Zimbabwe, United Kingdom, the Netherlands, Sweden and Belgium (sorted by frequency, only countries to which  ≥ 2 have reported travel is shown).

c Based on SARS-CoV-2 Delta variant cases from TCDK only (n = 18,549).

d One dose but not yet completed vaccination schedule (see footnote e).

e Vaccinated with two doses of Comirnaty (Pfizer/BioNTech, Mainz, Germany/ New York, United States), Vaxzevria (AstraZeneca, Cambridge, United Kingdom), Spikevax (Moderna, Cambridge, United States), or one dose of COVID-19 Vaccine Janssen (Johnson & Johnson, New Brunswick, United States) at least 14 days before positive test. By 9 December 2021, 76% of the Danish population had been fully vaccinated.

f Booster vaccination ca 6 months after being fully vaccinated and at least 14 days before positive test.

g Previous infection is defined as having a positive PCR tests more than 60 days from the current sample.